NLRP3-IN-42
NLRP3-IN-42 (compound H28) is a potent NLRP3 inhibitor with an KD value of 1.15 µM. NLRP3-IN-42 decreases the LPS (HY-D1056) induced protein expression of cleaved-caspase-1 (p20). NLRP3-IN-42 selectively inhibits IL-1β release.
For research use only. We do not sell to patients.
- CAS No.: 3040024-62-9
- Formula: C29H27F3N2O3S2
- Molecular Weight:572.66
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
NLRP3 1.15 μM (Kd) |
IL-1β |
In Vitro
NLRP3-IN-42 (compound H28) (0-30 µM) decreases the LPS (HY-D1056) induced protein expression of cleaved-caspase-1 (p20) in a dose-dependent manner[1].
NLRP3-IN-42 can stably bind to the ADP active site of the NLRP3 NACHT domain[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:J774A.1 cells
-
Concentration:0, 3, 10, 30 µM
-
Incubation Time:2.5 h + 30 min
-
Result:Decreased the LPS (1 μg/mL) induced protein expression of cleaved-caspase-1 (p20) in culture supernatants (SN) and whole cell lysates (WCL) in a dose-dependent manner.
In Vivo
Pharmacokinetic Parameters (ICR mice)[1].
| PK parameters | H28 |
| Administered dose (mg/kg) | iv at 2.5 mg/kg |
| AUC0-∞ (h*ng/mL) | 1189 ± 137 |
| t1/2 (h) | 1.69 ± 0.38 |
| CL (mL/h/kg) | 35.36 ± 4.12 |
| Cmax (ng/mL) | 2987 ± 281 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4-8 weeks, Male C57BL/6 mice[1]
-
Dosage:10 mg/kg
-
Administration:I.p; 1 h before injection of LPS (35 mg/kg, ip) for 2.5 h
-
Result:Significantly inhibited IL-1β production in the treatment mice. It is noteworthy that the treatment with these compounds do not result in significant inhibition of TNF-α levels.
Chemical Information
-
CAS No. 3040024-62-9
-
Molecular Weight 572.66
-
Formula C29H27F3N2O3S2
-
SMILES
CCCNS(=O)(C1=CC=C(C2=CC=CC=C2N(CC3=CC=C(C(F)(F)F)C=C3)C(CC4=CSC=C4)=O)C=C1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)